Effects of simvastatin on bone turnover and BMD: A 1-year randomized controlled trial in postmenopausal osteopenic women

Journal of Bone and Mineral Research

Volumn 19, Issue 5, 2004, Pages 737-744

  Rejnmark, Lars ^a,b   Buus, Niels Henrik ^a,b   Vestergaard, Peter ^a,b   Heickendorff, Lene ^a   Andreasen, Frederik ^b   Larsen, Mogens Lytken ^a   Mosekilde, Leif ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Bone densitometry; Bone turnover markers; Clinical trials; Osteoporosis; Treatments

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PLACEBO; SIMVASTATIN; ALKALINE PHOSPHATASE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; OSTEOCALCIN; PEPTIDE; TRIACYLGLYCEROL;

ARTICLE; BONE DENSITY; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; POSTMENOPAUSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SPINE; AGED; BLOOD; BODY COMPOSITION; BODY WEIGHT; BONE; BONE REMODELING; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

AGED; ALKALINE PHOSPHATASE; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY WEIGHT; BONE AND BONES; BONE DENSITY; BONE REMODELING; CHOLESTEROL; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; SIMVASTATIN; TRIGLYCERIDES;

EID: 3242799093     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040209     Document Type: Article

References (24)

1. Anonymous 1993 Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646-650.
2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G 1999 Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949.
3. Oxlund H, Dalstra M, Andreassen TT 2001 Stalin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69:299-304.
4. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S 2001 Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21:1636-1641.
5. Edwards CJ, Hart DJ, Spector TD 2000 Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218-2219.
6. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA 2000 HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142.
7. Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, Lucani B, Gennari C 2003 Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal study. Bone 32:427-433.
8. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R 2000 Inhibitors of hydromethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188.
9. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H 2000 HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210.
10. Wang PS, Solomon DH, Mogun H, Avorn J 2000 HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216.
11. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC 2002 Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537-540.
12. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C 2001 Use of statins and risk of fractures. JAMA 285:1850-1855.
13. Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S 2002 Relation of statin use and bone loss: A prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537-541.
14. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L 2002 Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur J Clin Invest 32:581-589.
15. Pedersen TR, Kjekshus J 2000 Statin drugs and the risk of fracture. 4S Study Group. JAMA 284:1921-1922.
16. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N 2001 Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term intervention with Pravastatin in ischaemic disease. Lancet 357:509-512.
17. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD 2003 Statin use, clinical fracture, and bone density in postmenopausal women: Results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104.
18. Brown J, Madit N, Cole ET, Wilding IR, Cade D 1998 The effect of cross-linking on the in vivo disintegration of hard gelatin capsules. Pharmacol Res 15:1026-1030.
19. Rosenquist C, Qvist P, Bjarnason N, Christiansen C 1995 Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445.
20. Kjekshus J, Pedersen TR 1995 Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76:64C-68C.
21. Li CY, Sung FC 1999 A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond) 49:225-229.
22. Froom P, Melamed S, Kristal-Boneh E, Benbassat J, Ribak J 1999 Healthy volunteer effect in industrial workers. J Clin Epidemiol 52:731-735.
23. Ray WA, Daugherty JR, Griffin MR 2002 Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276-279.
24. Wishart J, Horowitz M, Need A, Nordin BE 1990 Relationship between forearm and vertebral mineral density in postmenopausal women with primary hyperparathyroidism. Arch Intern Med 150:1329-1331.